Press Releases

Date Title View
Toggle SummaryFebruary 13, 2018 GenMark Diagnostics Schedules Fourth Quarter and Full Year 2017 Financial Results Conference Call for February 27, 2018
CARLSBAD, Calif. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Tuesday, February 27, 2018. Management will hold a conference call to review the Company's financial
View HTML
Toggle SummaryJanuary 9, 2018 GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2017
CARLSBAD, Calif. , Jan. 09, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2017 .
View HTML
Toggle SummaryDecember 21, 2017 GenMark Diagnostics to Present at the J.P. Morgan 36th Annual Healthcare Conference
CARLSBAD, Calif. , Dec. 21, 2017 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany , will present at the J.P.
View HTML
Toggle SummaryNovember 7, 2017 GenMark Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
CARLSBAD, Calif. --(BUSINESS WIRE)--Nov. 7, 2017-- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany , will present at the Canaccord Genuity Medical
View HTML
Toggle SummaryNovember 2, 2017 GenMark Diagnostics Reports Third Quarter 2017 Results
CARLSBAD, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2017 .
View HTML
Toggle SummaryOctober 19, 2017 GenMark Diagnostics Schedules Third Quarter 2017 Financial Results Conference Call for November 2, 2017
CARLSBAD, Calif. --(BUSINESS WIRE)--Oct. 19, 2017-- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 2, 2017 . Management will hold a conference call to review the Company's financial
View HTML
Toggle SummaryOctober 19, 2017 GenMark Diagnostics Schedules Third Quarter 2017 Financial Results Conference Call for November 2, 2017
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 2, 2017 . Management will hold a conference call to review the Company's financial performance starting
View HTML
Toggle SummaryAugust 1, 2017 GenMark Reports Second Quarter 2017 Results
Second Quarter Revenue of $12.4 million Ended the Quarter with Over 80 ePlex ® Instruments Installed at Customer Sites CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced
View HTML
Toggle SummaryJuly 31, 2017 GenMark Diagnostics to Attend Canaccord Genuity's 37th Annual Growth Conference
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that President and Chief Executive Officer, Hany Massarany , will attend the 2017 Canaccord Genuity Growth Conference in
View HTML
Toggle SummaryJune 29, 2017 GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Gram-Positive and Gram-Negative Panels
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices Directive (98/79/EC) for its ePlex Blood Culture
View HTML